MedTech News
.................... by Andrew Celentano
New approach cuts sepsis diagnosis from days to hours
Sepsis, a life-threatening condition that stems from the body trying to fight off an infection, plagues more than 1.5 million patients a year in the U.S. alone, with one in three deaths recorded in hospitals attributed in part to sepsis. Despite the severity of the condition, which can kill in as little as 12 hours, it takes between two and seven days for most traditional approaches to definitively identify sepsis-causing bacteria in blood infections.
Prostate medication linked to fewer complications after heart attack
Men are likely to suffer more extensive heart attacks than women. Studies have shown that male sex hormones, such as testosterone, intensify inflammation during an acute heart attack and lead to a larger area of damage. According to a study from the University of Gothenburg, patients treated with medication for benign prostatic hyperplasia at the time of a severe acute heart attack experienced fewer serious complications from the attack.
Cancer is quantum: Studies show cancer cells may occupy limited, shared states like quantized energy levels
Andrea Califano began his career as a physicist. But that’s not why he’s now calling cancer a quantum disease. “We’re really just following the data,” says Califano, the Clyde ’56 and Helen Wu Professor of Chemical Biology at Columbia University Vagelos College of Physicians and Surgeons and head of Biohub, New York.
Spineart and eCential Robotics receive FDA 510(k) clearance for the PERLA® TL application for use with eCential® Op.n® navigation system for robotic procedures.
GENEVA, Aug. 26, 2026 /PRNewswire/ — Spineart, a global fast-growing company in spine surgery innovation, and eCential Robotics today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the PERLA® TL application (PERLA® by Spineart app) for use with the eCential® Op.n® Navigation and Robotic-Assisted Platform.
Jazz scores front-line gastric cancer nod from FDA for ‘practice-changing’ Ziihera
Gastroesophageal adenocarcinoma presents the biggest market opportunity for Jazz Pharmaceuticals’ Ziihera, according to Truist Securities, which forecasts peak sales of the drug to reach $2.5 billion.
FDA approves Abbott’s Libre Duo 10 Day dual glucose-ketone monitor
The Libre Duo 10 Day sensor delivers up to ten days of continuous monitoring with ongoing readings, not single-point measurements.
ESC 2026: AI able to detect diabetes from facial video recordings
The University of Tokyo and Institute of Science Tokyo’s AI detected diabetes with accuracy >80% from 30-second and five-seconds recordings.
Restoring aging T cell function to make them effective at fighting cancer
In a new study, Mass General Brigham researchers explore the causes of immune aging, a barrier to successful cancer immunotherapy, and identify a gene that may serve as an age-related prognostic marker and potential target for future cancer therapies.